Ball valve (Smeloff-Cutter) aortic valve replacement without anticoagulation

Area of Science:

• Cardiovascular Surgery
• Biomaterials Science
• Clinical Outcomes Research

Background:

• Permanent anticoagulation is challenging for young patients requiring aortic valve replacement.
• Smeloff-Cutter mechanical valves have been used since 1986 for selected patients avoiding long-term anticoagulation.
• This study evaluates the outcomes of this specific valve in a young cohort.

Purpose of the Study:

• To assess the efficacy and safety of Smeloff-Cutter ball valves for aortic valve replacement in young patients.
• To determine long-term survival and embolic event rates in this patient group.
• To evaluate the need for reoperation and compare outcomes with antiaggregant therapy.

Main Methods:

• Retrospective analysis of 47 patients undergoing aortic valve replacement with Smeloff-Cutter valves since July 1988.
• Patients were followed for a mean of 43.2 months (range, 16-78 months).
• Data collected included demographics, procedural details, survival, embolic events, and reoperations.

Main Results:

• Actuarial survival at 6 years was 91% +/- 4.3%, with no hospital deaths.
• Five embolic events occurred (2.9%/patient-year); incidence was lower for isolated aortic valve replacement with antiaggregant therapy (0.9%/patient-year).
• Reoperation was required in 5 patients; no cases of valve thrombosis were reported.

Conclusions:

• Aortic valve replacement using Smeloff-Cutter ball valves is a potential alternative for young patients.
• Careful patient selection is crucial for successful outcomes.
• Further research may explore optimizing antiplatelet strategies in conjunction with these valves.